HRP20211967T1 - Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka - Google Patents
Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka Download PDFInfo
- Publication number
- HRP20211967T1 HRP20211967T1 HRP20211967TT HRP20211967T HRP20211967T1 HR P20211967 T1 HRP20211967 T1 HR P20211967T1 HR P20211967T T HRP20211967T T HR P20211967TT HR P20211967 T HRP20211967 T HR P20211967T HR P20211967 T1 HRP20211967 T1 HR P20211967T1
- Authority
- HR
- Croatia
- Prior art keywords
- deoxyuridine
- fluoro
- phosphate
- naphthyl
- alaninyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103582.1A GB201103582D0 (enExample) | 2011-03-01 | 2011-03-01 | |
| GBGB1105660.3A GB201105660D0 (en) | 2011-04-01 | 2011-04-01 | Chemical compounds |
| EP18178715.1A EP3447061B1 (en) | 2011-03-01 | 2012-02-29 | Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211967T1 true HRP20211967T1 (hr) | 2022-03-18 |
Family
ID=45841523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211967TT HRP20211967T1 (hr) | 2011-03-01 | 2012-02-29 | Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka |
| HRP20160346TT HRP20160346T1 (hr) | 2011-03-01 | 2012-02-29 | Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160346TT HRP20160346T1 (hr) | 2011-03-01 | 2012-02-29 | Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8933053B2 (enExample) |
| EP (4) | EP3447061B1 (enExample) |
| JP (1) | JP5978232B2 (enExample) |
| KR (1) | KR101885940B1 (enExample) |
| CN (2) | CN103403013B (enExample) |
| AU (1) | AU2012223012C1 (enExample) |
| BR (1) | BR112013021986B1 (enExample) |
| CA (1) | CA2828326C (enExample) |
| CL (1) | CL2013002517A1 (enExample) |
| CY (2) | CY1117445T1 (enExample) |
| DK (3) | DK2681227T3 (enExample) |
| ES (4) | ES2686219T3 (enExample) |
| HR (2) | HRP20211967T1 (enExample) |
| HU (2) | HUE029022T2 (enExample) |
| IL (1) | IL228169A (enExample) |
| LT (1) | LT3447061T (enExample) |
| MX (1) | MX339822B (enExample) |
| NZ (1) | NZ615270A (enExample) |
| PH (2) | PH12013501723A1 (enExample) |
| PL (3) | PL3031812T3 (enExample) |
| PT (2) | PT3447061T (enExample) |
| RS (2) | RS62721B1 (enExample) |
| RU (1) | RU2614406C2 (enExample) |
| SG (1) | SG192841A1 (enExample) |
| SI (2) | SI3447061T1 (enExample) |
| SM (2) | SMT202100715T1 (enExample) |
| WO (1) | WO2012117246A1 (enExample) |
| ZA (2) | ZA201306468B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| CA2828326C (en) | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| JP2016506371A (ja) | 2012-11-16 | 2016-03-03 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | ヌクレオシドプロドラッグを調製する方法 |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
| RU2553996C1 (ru) * | 2013-11-27 | 2015-06-20 | Андрей Александрович Иващенко | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| KR20170005492A (ko) * | 2014-05-28 | 2017-01-13 | 아이데닉스 파마슈티칼스 엘엘씨 | 암의 치료를 위한 뉴클레오시드 유도체 |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| SI3160978T1 (sl) | 2014-06-25 | 2020-11-30 | NuCana plc | Gemcitabin predzdravila |
| PL225283B1 (pl) * | 2014-07-24 | 2017-03-31 | Univ Im Adama Mickiewicza W Poznaniu | Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie |
| US10570168B2 (en) | 2014-11-28 | 2020-02-25 | NuCana plc | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| EP3303361A1 (en) * | 2015-05-27 | 2018-04-11 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of cancer |
| WO2017087517A1 (en) * | 2015-11-16 | 2017-05-26 | Demeter Therapeutics, Llc | Nucleic acid prodrugs |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| EP3865136A1 (en) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for corona virus treatment |
| MX2019005466A (es) | 2016-11-13 | 2019-10-02 | Imagine Pharma | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. |
| CN109863160B (zh) | 2016-12-23 | 2022-06-07 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酸类化合物及其制备方法和用途 |
| RU2644156C1 (ru) * | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| AU2017426847B2 (en) * | 2017-08-08 | 2021-11-18 | Sun Yat-Sen University | Methods and compositions for treatment of multi-drug resistant tumors |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) * | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| US11597745B2 (en) * | 2018-03-09 | 2023-03-07 | Japan Science And Technology Agency | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction |
| CN110387226A (zh) * | 2018-04-20 | 2019-10-29 | 天津大学 | 一种用于检测肿瘤的荧光探针及用途 |
| US12221649B2 (en) | 2018-11-30 | 2025-02-11 | The University Of Tokyo | Fluorescent probe for detecting carboxypeptidase activity |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| CN110840907B (zh) * | 2019-08-16 | 2022-11-25 | 南京医科大学 | 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN116368143A (zh) * | 2020-08-31 | 2023-06-30 | 埃莫里大学 | 5'-取代的单磷酸核苷、其前药及其相关用途 |
| EP4630433A1 (en) | 2022-12-07 | 2025-10-15 | NuCana plc | Synthesis of nucleoside derivative nuc-3373 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US1002239A (en) | 1902-04-11 | 1911-09-05 | Stromberg Carlson Telephone | Telephone system. |
| US2945038A (en) | 1956-09-26 | 1960-07-12 | Hoffmann La Roche | 5-fluorocytosine and preparation thereof |
| US3201387A (en) | 1963-09-18 | 1965-08-17 | Heidelberger Charles | 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| DD279248A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| WO1999037753A1 (en) * | 1998-01-23 | 1999-07-29 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
| AU775601B2 (en) | 1999-07-22 | 2004-08-05 | Celmed Oncology (Usa) Inc. | Enzyme catalyzed therapeutic activation |
| DE10109657A1 (de) | 2001-02-28 | 2002-09-05 | Menarini Ricerche Spa | Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin |
| WO2003000713A1 (en) | 2001-06-21 | 2003-01-03 | Glaxo Group Limited | Nucleoside compounds in hcv |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| EP1827460A4 (en) | 2004-12-09 | 2012-03-14 | Univ Minnesota | NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| CN101922935B (zh) | 2010-07-16 | 2012-07-18 | 北京大学 | 一种最小互易结构干涉型全光纤陀螺仪 |
| PT2596004E (pt) | 2010-07-19 | 2014-11-28 | Gilead Sciences Inc | Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CN105061534A (zh) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
| WO2012048013A2 (en) | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| CA2828326C (en) * | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| HUE026338T2 (en) | 2011-03-01 | 2016-05-30 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| BR112016025787B1 (pt) | 2014-06-25 | 2022-12-13 | NuCana plc | Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma |
| US10570168B2 (en) | 2014-11-28 | 2020-02-25 | NuCana plc | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds |
| DK3197456T3 (en) | 2015-05-14 | 2018-06-06 | NuCana plc | CANCER TREATMENTS |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2012
- 2012-02-29 CA CA2828326A patent/CA2828326C/en active Active
- 2012-02-29 HU HUE12709146A patent/HUE029022T2/en unknown
- 2012-02-29 DK DK12709146.0T patent/DK2681227T3/da active
- 2012-02-29 PT PT181787151T patent/PT3447061T/pt unknown
- 2012-02-29 NZ NZ615270A patent/NZ615270A/en unknown
- 2012-02-29 MX MX2013009815A patent/MX339822B/es active IP Right Grant
- 2012-02-29 ES ES16150494.9T patent/ES2686219T3/es active Active
- 2012-02-29 CN CN201280010761.4A patent/CN103403013B/zh active Active
- 2012-02-29 RS RS20211549A patent/RS62721B1/sr unknown
- 2012-02-29 HR HRP20211967TT patent/HRP20211967T1/hr unknown
- 2012-02-29 RS RS20160211A patent/RS54776B1/sr unknown
- 2012-02-29 ES ES18178715T patent/ES2903097T3/es active Active
- 2012-02-29 SM SM20210715T patent/SMT202100715T1/it unknown
- 2012-02-29 EP EP18178715.1A patent/EP3447061B1/en active Active
- 2012-02-29 HU HUE18178715A patent/HUE060127T2/hu unknown
- 2012-02-29 PT PT16150494T patent/PT3031812T/pt unknown
- 2012-02-29 LT LTEP18178715.1T patent/LT3447061T/lt unknown
- 2012-02-29 EP EP12709146.0A patent/EP2681227B1/en active Active
- 2012-02-29 KR KR1020137025749A patent/KR101885940B1/ko active Active
- 2012-02-29 JP JP2013555935A patent/JP5978232B2/ja active Active
- 2012-02-29 WO PCT/GB2012/050457 patent/WO2012117246A1/en not_active Ceased
- 2012-02-29 CN CN201510329656.2A patent/CN104974206B/zh active Active
- 2012-02-29 AU AU2012223012A patent/AU2012223012C1/en active Active
- 2012-02-29 ES ES12709146.0T patent/ES2569185T3/es active Active
- 2012-02-29 PL PL16150494T patent/PL3031812T3/pl unknown
- 2012-02-29 SI SI201231972T patent/SI3447061T1/sl unknown
- 2012-02-29 HR HRP20160346TT patent/HRP20160346T1/hr unknown
- 2012-02-29 PL PL18178715T patent/PL3447061T3/pl unknown
- 2012-02-29 EP EP21209926.1A patent/EP4023299B1/en active Active
- 2012-02-29 EP EP16150494.9A patent/EP3031812B1/en active Active
- 2012-02-29 PL PL12709146T patent/PL2681227T3/pl unknown
- 2012-02-29 SG SG2013062823A patent/SG192841A1/en unknown
- 2012-02-29 BR BR112013021986-6A patent/BR112013021986B1/pt active IP Right Grant
- 2012-02-29 DK DK18178715.1T patent/DK3447061T3/da active
- 2012-02-29 SI SI201230488T patent/SI2681227T1/sl unknown
- 2012-02-29 DK DK16150494.9T patent/DK3031812T3/en active
- 2012-02-29 RU RU2013143862A patent/RU2614406C2/ru active
- 2012-02-29 PH PH1/2013/501723A patent/PH12013501723A1/en unknown
- 2012-02-29 US US14/000,682 patent/US8933053B2/en active Active
- 2012-02-29 ES ES21209926T patent/ES3039965T3/es active Active
-
2013
- 2013-08-28 IL IL228169A patent/IL228169A/en active IP Right Grant
- 2013-08-30 CL CL2013002517A patent/CL2013002517A1/es unknown
- 2013-09-09 ZA ZA2013/06468A patent/ZA201306468B/en unknown
-
2014
- 2014-12-04 US US14/560,097 patent/US9221866B2/en active Active
- 2014-12-09 ZA ZA2014/09013A patent/ZA201409013B/en unknown
-
2015
- 2015-03-05 PH PH12015500485A patent/PH12015500485A1/en unknown
- 2015-11-17 US US14/943,555 patent/US9655915B2/en active Active
-
2016
- 2016-04-27 CY CY20161100360T patent/CY1117445T1/el unknown
- 2016-05-06 SM SM201600132T patent/SMT201600132B/it unknown
-
2017
- 2017-04-18 US US15/489,884 patent/US10022390B2/en active Active
-
2018
- 2018-06-28 US US16/021,103 patent/US10993957B2/en active Active
-
2021
- 2021-04-06 US US17/223,241 patent/US11559542B2/en active Active
- 2021-12-17 CY CY20211101114T patent/CY1124871T1/el unknown
-
2023
- 2023-01-11 US US18/095,937 patent/US11925658B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211967T1 (hr) | Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka | |
| CY1124728T1 (el) | Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων | |
| AR122902A2 (es) | Compuestos terapéuticamente activos y sus métodos de preparación | |
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| JP2015500795A5 (enExample) | ||
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| JP2016519062A5 (enExample) | ||
| JP2017036314A5 (enExample) | ||
| JP2015143283A5 (enExample) | ||
| RU2015126856A (ru) | Дисульфидные маскированные пролекарственные композиции и способы | |
| RU2015148010A (ru) | Высокоактивное производное нуклеозида для лечения hcv | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| CY1114647T1 (el) | Παραγωγο (αζα)και χρηση αυτου για ιατρικους σκοπους | |
| EA201000614A1 (ru) | Производные пурина как лиганды аденозинового рецептора а | |
| CY1115657T1 (el) | Θεραπεια της μυϊκης δυστροφιας duchenne | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| JP2009530392A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| HRP20140621T1 (hr) | Sinteza neurostimulativnog piperazina | |
| JP2013515037A5 (enExample) | ||
| EA200971044A1 (ru) | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина | |
| AR054277A1 (es) | Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst. |